novel group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells.
June 4, 2020
novel group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells.
The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.
